TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies

https://doi.org/10.1056/NEJMoa2517384

Expert Insights on Achieving Normalization for Hemophilia A Patients

This article features Cedric Hermans, MD, PhD, FRCP, a professor and head of hematology at Saint-Luc University Hospital in Brussels, discus

Acute versus Long-term anti-GPVI Treatment: From Receptor Blockade to Partial Downregulation

CME Event: From Treatment Advances to Individualized Care in Hemophilia - August 2026

A CME/CNE/CPE/IPCE educational event titled "From Treatment Advances to Individualized Care in Hemophilia" scheduled for August 14, 2026, at

Lenacapavir and the shift to NRTI-free, long-acting HIV treatment: implications for HBV patients

The article discusses the evolving HIV treatment landscape, focusing on the shift toward NRTI-free dual regimens and long-acting injectable

Une révolution ? Ce gel injectable pourrait non seulement soigner l’arthrose mais aussi permettre aux médecins de suivre le traitement en direct